Palliative radiotherapy in liver metastases and HCC

Laura A. Dawson, MD, FASTRO, Princess Margaret Cancer Centre, Toronto, Canada, provides an overview of findings from a Phase III trial (NCT02511522) assessing the efficacy of palliative radiotherapy in patients with hepatocellular carcinoma (HCC) and liver metastases. Patients were randomized to either receive one dose of palliative radiotherapy or the best standard of care. The addition of palliative radiotherapy significantly reduced pain in patients, as well as quality of life and 3-month survival rates. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.